SIRT

SIRT

Besides HDACs, multiple sirtuins (NAD+-dependent deacetylase sirtuin, SIRT; EC 3.5.1.98) are known to show deacetylase activity. They are considered class III histone deacetylases that deacetylate histones and transcription factors. In turn, sirtuins can be inhibited by nicotinamide, which binds to a specific receptor site of the enzyme, so it is thought that drugs that interfere with this binding should increase sirtuin activity. Development of new agents that would specifically block the nicotinamide-binding site could provide an avenue for development of newer agents to treat degenerative diseases such as cancer, Alzheimer\'s, diabetes, atherosclerosis, and gout.SIRT1 is involved in other signaling pathways as well, since it competes with HDAC1 in deacetylation of PTEN, an important phosphatase involved in cell signaling via phosphoinositols and the PI3K/AKT/mTOR signaling pathway. Aiming to keep up with these recent developments in oncology research,Axon Medchem recently added a significant number of HDAC inhibitors to its ever broadening range of products.

Read More
sort-descending
  • SRT 1720 tetrahydrochloride
    1875
    SRT 1720 tetrahydrochloride
    The price depends on the options chosen on the product page

    From $104.50

  • Selisistat
    1956
    Selisistat
    The price depends on the options chosen on the product page

    From $99.00

  • Tenovin 1
    2008
    Tenovin 1
    The price depends on the options chosen on the product page

    From $77.00

  • Tenovin 6
    2249
    Tenovin 6
    The price depends on the options chosen on the product page

    From $115.50

  • AK 1
    2269
    AK 1
    The price depends on the options chosen on the product page

    From $99.00

  • AK 7
    2270
    AK 7
    The price depends on the options chosen on the product page

    From $99.00

  • SirReal 2
    2453
    SirReal 2
    The price depends on the options chosen on the product page

    From $104.50

  • Salermide
    2704
    Salermide
    The price depends on the options chosen on the product page

    From $104.50

  • Cambinol
    2803
    Cambinol
    The price depends on the options chosen on the product page

    From $104.50

  • OSS-128167
    2843
    OSS-128167
    The price depends on the options chosen on the product page

    From $137.50

  • SIRT7 inhibitor 97491
    2968
    SIRT7 inhibitor 97491
    The price depends on the options chosen on the product page

    From $148.50

  • Recently added
    AGK2
    3052
    AGK2
    The price depends on the options chosen on the product page

    From $121.00

  • Sirtinol
    3908
    Sirtinol
    The price depends on the options chosen on the product page

    From $99.00

  • 2-APQC
    4282
    2-APQC
    The price depends on the options chosen on the product page

    From $176.00

14 Items

More About SIRT

Besides HDACs, multiple sirtuins (NAD+-dependent deacetylase sirtuin, SIRT; EC 3.5.1.98) are known to show deacetylase activity. They are considered class III histone deacetylases that deacetylate histones and transcription factors[1]. In turn, sirtuins can be inhibited by nicotinamide, which binds to a specific receptor site of the enzyme, so it is thought that drugs that interfere with this binding should increase sirtuin activity. Development of new agents that would specifically block the nicotinamide-binding site could provide an avenue for development of newer agents to treat degenerative diseases such as cancer, Alzheimer's, diabetes, atherosclerosis, and gout[2].
SIRT1 is involved in other signaling pathways as well, since it competes with HDAC1 in deacetylation of PTEN, an important phosphatase involved in cell signaling via phosphoinositols and the PI3K/AKT/mTOR signaling pathway. Aiming to keep up with these recent developments in oncology research,Axon Medchem recently added a significant number of HDAC inhibitors to its ever broadening range of products.

[1] Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. S. Hisahara et al. PNAS 2008, 105, 15599-15604.
[2] Sirtuin activators. F.J. Alcaín, J.M. Villalba. Exp. Opin. Ther. Pat. 2009, 19, 403-414.

Loading...